Xarelto Bleeding Lawsuits Continue With Consolidation Hearing This Week In South Carolina Court Notes Wright & Schulte LLC

Print

A Panel Of Federal Judges Will Consider Consolidating Xarelto Lawsuits Which Contend People Suffered Severe Bleeding Due To The Blood Thinner Medication.

xarelto-bleeding-lawsuits-Wright-and-Schulte-LLCAs Xarelto bleeding lawsuits filings continue to mount, a federal judicial panel prepares to hear oral arguments Thursday on consolidating all Xarelto complaints in the U.S. District Court, Southern District of Illinois. The U.S. Judicial Panel on Multidistrict Litigation (JPML) has scheduled a hearing in the U.S. District Court, District of South Carolina in Charleston to allow plaintiffs in six Xarelto complaints to present their request to centralize Xarelto bleeding lawsuits into a multidistrict litigation (MDL). The Xarelto blood thinner lawsuits have been filed against Beyer Corp. and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals Inc., the makers and marketers of Xarelto. The lawyers were filed on behalf of individuals who have taken the blood thinner medication and allegedly suffered significant bleeding events and death because Xarelto has no reversal agent should uncontrolled bleeding occur. Wright & Schulte LLC notes that lawsuits in a MDL have common questions of fact and the JPML decides whether to centralize these complaints into one court for pretrial proceedings and discovery. Although the complaints in a MDL are consolidated, the cases are tried individually. In November, Beyer and Janssen asked the JMPL to deny the request to consolidate the Xarelto lawsuits and allow the parties to informally coordinate the lawsuits among themselves. (In Re: Xarelto Products Liability Litigation, MDL No. 2592, JPML)

Xarelto is considered a new generation blood thinner which the U.S. Food and Drug Administration (FDA) approved to treat deep vein thrombosis and pulmonary embolism and to reduce the risk of these conditions from occurring following the initial treatment. The oldest blood thinner on the market is warfarin (marketed as Coumadin or Jantoven) which the FDA approved in 1954. Xarelto was first approved by the FDA in July 2011 to reduce the risk of blood clots in patients who had knee or hip replacement surgery. In November 2011, the FDA approved Xarelto to reduce the risk of stroke and blood clots in patients with atrial fibrillation (irregular heart rhythms). According to the FDA, Xarelto’s major side effect is bleeding and unlike warfarin which has vitamin K as an antidote, Xarelto does not have a reversal agent should severe bleeding occur.
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm, November 2, 2012]
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

According to the plaintiffs’ motion to the JPML filed in October, there were an estimated 21 Xarelto complaints filed in 10 different federal courts at the time. Another document recently filed to the JPML states there are more Xarelto lawsuits pending. In November, an Interested Party Response was filed by attorneys who represent more than 50 additional Xarelto users from 21 different states with lawsuits pending in various federal courts. The attorneys said in their document to the JPML that they expect “many more lawsuits” to be filed in the near future alleging injuries and damages caused by the Xarelto blood thinner medication. (In Re: Xarelto Products Liability Litigation–MDL No. 2592)

Court documents indicate that one of the attorneys named in the Interested Party Response also filed a Xarelto lawsuit on behalf of two plaintiffs who allege that their 92-year-old father died as a result of using Xarelto. According to the Xarelto complaint, the father was prescribed the blood thinner in May 2013 by his primary care physician. The blood thinner medication lawsuit alleges that the man experienced a life-threatening bleeding in August 2013 as a result of using Xarelto. The lawsuit further alleges that the man died on December 6, 2013, after experiencing an uncontrollable gastrointestinal bleeding. The Xarelto blood thinner complaint purports that Beyer and Janssen knew about the side-effects of Xarelto but failed to inform Xarelto patients about the risks associated with the blood thinner medication. The lawsuit was filed in the U.S. District Court, Eastern District of New York (Case No: 1:14-cv-04841).

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Xarelto bleeding lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact: Wright & Schulte LLC 865 S. Dixie Dr. Vandalia, Ohio 45377 1-800-399-0795
http://www.yourlegalhelp.com

Like us on https://www.facebook.com/WrightSchulteLLC?ref=hl [Facebook __title__ https://www.facebook.com/WrightSchulteLLC?ref=hl]
Follow us on https://twitter.com/YourLegal_Help [Twitter __title__ https://twitter.com/YourLegal_Help]
Join us on https://plus.google.com/b/111854447521676635423/111854447521676635423/posts?hl=en&pageId=111854447521676635423 [Google+ __title__ Google+]

This entry was posted in Wright & Schulte Lawsuit News. Bookmark the permalink.